Clinical trial BGB-A317-210/TIRHOL
A Phase 2, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (BGB-A317-210/TIRHOL)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Lysarc |
| EudraCT Identifier | 2019-002105-22 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04318080 |
| Inclusion criteria | - Relapsed cHL (disease progression after PR or CR to the most recent therapy) or refractory cHL (failure to achieve PR or CR to most recent therapy)- Prior therapy targeting PD-1 or PD-L1, anti-PD-L2, or anti CTLA-4 agent = exclusion criteria |
| Last update |